Although the precise mechanism of endotoxin lethality has yet to be defined, it is well recognized that the amount of hepatic phosphoenolpyruvate carboxykinase is reproducibly and significantly reduced after challenge with endotoxin. Hydrazine has been shown to be a specific inhibitor of gluconeogenesis, causing a metabolic crossover at the step catalyzed by phosphoenolpyruvate carboxykinase. More recently, it has also been shown that hydrazine sulfate may be of potential therapeutic value against cancer cachexia. The experiments described in this paper demonstrate that treatment of CF1 mice with hydrazine sulfate 5 h prior to challenge with endotoxin from Salmonella enteriditis significantly improved survival. Furthermore, such treatment counteracted the drop in hepatic phosphoenolpyruvate carboxykinase activity in isolated cytosol otherwise evident at 6 h and 12 h after endotoxin challenge. Despite this, there was no corresponding improvement in the plasma glucose, measured at 6, 12, and 24 h following endotoxin challenge. It is suggested that the endogenous response to the metabolic crossover initiated by hydrazine may contribute to the protection. The response to hydrazine sulfate has yet to be fully elaborated but does include the increase in phosphoenolpyruvate carboxykinase activity. In contrast with the protection seen upon hydrazine sulfate pretreatment, injecting a corresponding dose of hydrazine sulfate after the endotoxin resulted in more fatalities.
One of the characteristics of endotoxin (lipopolysaccharide [LPS]) shock is a potentially lethal hypoglycemia (3).
Another characteristic feature is an early decrease in hepatic phosphoenolpyruvate carboxykinase (PEPCK; 27). This enzyme has been reported to catalyze the rate-limiting step of the gluconeogenic pathway from oxaloacetate (33) and is regulated by several hormones at the level of its transcription (11, 18, 38) . Accordingly, the decreased PEPCK may be an immediate cause of the LPS-induced hypoglycemia (25) .
Several developments have suggested that hydrazine sulfate (HS) might prove beneficial against LPS-induced lethality, notwithstanding the fact that HS has long been known to cause hypoglycemia and even be fatal in sufficiently high doses (40) . First, Lardy and co-workers investigated the basis for the HS hypoglycemic effect, showing that not only is HS a classical noncompetitive inhibitor of PEPCK in vitro but that in vivo it causes a metabolic crossover in the gluconeogenic pathway at the step catalyzed by PEPCK. Furthermore, PEPCK activity in isolated liver cytosol was found to increase with time following the initial HS injection. It was suggested that this might be a result of an adrenal response to the initial drop in the blood glucose, leading to new PEPCK synthesis. The drop in glucose was rapid and completely reversed by 4 h, even at an HS dose of 264 mg/kg 2 mmol (32) . A second potentially relevant finding has been the recent clinical evidence that HS may be of potential therapeutic value against cancer cachexia (9, 10) . Experiments by one of us (R.S.) to develop a suitable animal model of cancer cachexia were unsuccessful but did show that daily injections of 20 mg of HS per kg to rats for 2 or 3 weeks leads to a sustained (24-h) increase in hepatic PEPCK activity from both control and cancerous inbred rats (35) . Third, the discovery that tumor necrosis factor (TNF) and cachectin are the same molecule (6) , plus the demonstration that cachectin may be an important mediator in LPS lethality * Corresponding author. (39) , has led to the concept that cachexia associated with a number of different disease states, including sepsis, cancer, and possibly acquired immunodeficiency syndrome, may, in some instances, be linked (5, 21, 28) . Taken together, these observations suggested that the concept of HS as potentially beneficial against LPS might merit experimental investigation. This report demonstrates that under defined experimental conditions and with appropriate HS dosage, HS pretreatment provides a level of protection against LPS lethality comparable to that observed with other therapeutic regimens. Of interest is that HS prevented the drop in hepatic PEPCK that is otherwise evident; however, the net effect on plasma glucose levels was negligible.
MATERIALS AND METHODS Animals. CF1 female mice, age 6 to 8 weeks, were purchased from Charles River Laboratories and were maintained on Purina mouse chow. At the time of the experiments, mice were 18 to 28 g. Light and dark cycles were 12 h and were electrically timed.
Chemicals. LPS was isolated from Salmonella enteritidis by the phenol-water method (41 (24) .
Plasma glucose. Blood was taken from the trunk into heparin-coated tubes, via heparin-coated funnels, and the tubes were then placed on ice. The tubes contained 10 p1l of heparin (100 U) per ml of blood. The blood was centrifuged at 2,300 x g for 20 min at 4°C, and the plasma was then collected and frozen. Glucose was assayed with hexokinase and glucose 6-phosphate dehydrogenase by using a reagent kit as described by the manufacturer (Sigma).
Statistics. Chi-square contingency tables (2) were used to assess the significance of HS effects on LPS lethality. The enzyme activity and plasma glucose data are presented as plus or minus the standard error of the mean, with P values determined by the t test distribution method (13) .
RESULTS
We initially investigated whether HS might protect against LPS lethality using an experimental protocol in which 50 mg of HS per kg was administered intraperitoneally in a single dose into 25-g female CF1 mice. The HS was delivered 5 h prior to LPS challenge. The dose of LPS selected, in the absence of HS, was lethal to about 50 to 70% of the mice.
Comparison of the number of lethalities that resulted over a 72-h period after LPS injection in two experiments suggested that HS pretreatment might provide significant protection against LPS lethality (Fig. 1 ).
In the above experiment, lethality was determined as a consequence of a single concentration of LPS and with comparisons at a single fixed time following LPS challenge. Conceivably, HS might have simply shifted the time frame for the response to LPS, thus delaying lethality but without conferring true protection. Keeping the conditions for HS injection constant, both with respect to dose and time of delivery, while varying the dose of LPS in the challenge, gave data that indicated clear protection at each LPS concentration. HS protection against LPS lethality was evident both above and below the established LD50 dose ( Fig. 2A) .
Furthermore, the frequency of lethality in these experiments was determined at different fixed times during the course of the challenge. Comparison of cumulative lethality, with or without HS, under separate conditions of LPS dose such that the total number of fatalities at the end of the challenge were similar revealed no detectable differences in the time profiles of cumulative lethality ( Fig. 2A and B) . Accordingly, HS confers a true protection, and does not shift the time or dose response to LPS.
The effect of varying the HS dose on the degree of protection was next examined. In these experiments, the time of HS delivery was kept constant at 5 h prior to LPS, while doses both higher and lower than the 50 mg of HS per kg were tested. All other experimental parameters were maintained as described above. The results of these experiments are shown in Fig. 3 and suggest a bimodal character to the influence of HS on LPS lethality. At doses of 30 to 80 mg of HS per kg, protection was again confirmed, (P < 0.01); however, at the higher doses examined (120 or 160 mg of HS per kg), pretreatment actually enhanced the susceptibility of mice to the lethal effects of LPS.
Given this added dimension to the effect of HS on LPS lethality, even at a fixed time of HS delivery relative to LPS, it seemed reasonable to also examine the importance of time of HS injection relative to that of LPS. For these experiments, the HS dose was held constant at the previously determined protective dose of 50 mg/kg. The results of these experiments indicate that the time of HS delivery relative to LPS challenge was an important element for providing protection (Fig. 4) . A single injection of HS at the 50 mg/kg dose but at 1.5 or 12 h after the time of LPS injection, rather than protecting, increased the number of fatalities (Fig. 4) . (13) .
We have also shown that protection from HS was not limited to the particular time of 5 h prior to LPS but was also evident when 50 mg of HS per kg was administered at 1.3, 3, or 8 h prior to the LPS (data not shown).
As an initial approach toward elucidating the mechanisms responsible for the observed effects of HS on LPS lethality, we determined the consequences of HS injection on plasma glucose. These studies were predicated upon the well-recognized capacity of HS to effect a rapid and reversible drop in the blood glucose (32) . The effects of a single 50-or 120-mg/kg injection of HS on plasma glucose were therefore determined, with HS injected at 0800 h (corresponding to the protocol outlined in Fig. 1) . At a dose of 120 mg/kg, HS brought about a significant drop in plasma glucose at 1 h (P < 0.005), with a return to the control level by 5 h (Fig. 5 (Fig. 6) . Among the LPS-challenged mice that were given saline vehicle in place of HS, there was the expected drop in PEPCK activity (P < 0.005 at 6 h; P < 0.02 at 12 h). In the HS-pretreated mice, however, the changes in liver PEPCK levels at 6 and 12 h following LPS were essentially indistinguishable from those of the saline-treated control mice (P > 0.5). The variations in FBPase were also insignificant throughout (data not shown). In these experiments, mice were taken off feed throughout the period of LPS challenge, thus ensuring that any HS-induced changes in enzymespecific activities could not be attributed to differences in food intake. By 24 h, the PEPCK levels from the LPSchallenged mice had returned to those of controls, whether or not the mice had been pretreated with HS (data not shown).
The corresponding levels of plasma glucose ascertained from the same animals showed, as expected, a dramatic drop in plasma glucose that was sustained for at least 24 h following LPS. Nevertheless, HS pretreatment, rather unexpectedly, did not elicit a significant improvement in the plasma glucose (Fig. 7) . Thus, the HS-induced increase in PEPCK activity appears not to be translated into a net improvement in plasma glucose levels. To confirm that this was also the case under experimental conditions identical to those used during the lethality studies described above, the experiment was repeated. This time, however, the mice were placed back on feed at the time of LPS challenge. Again, the effect of HS on plasma glucose was minimal (Table 1) . Even combining and normalizing the 12-h datum points from Fig. 7 with the corresponding data from Table 1 showed an improvement in blood glucose levels that was only marginally significant (P < 0.1).
The question arises, therefore, as to whether a dose of 50 mg of HS per kg has an appreciable effect on plasma glucose at any time, including the circumstance of HS injection after the LPS. More specifically, does a 50-mg/kg dose of HS Fig. 6 , with blood taken at the time the mice were euthanized. Data are expressed as plus or minus the standard error of the mean (13) .
compound the drop in plasma glucose under conditions when HS exacerbates, rather than protects against, LPS lethality (e.g., when HS is delivered 1.5 h after the LPS)? The data in Table 2 , with three mice per group, show a consistent further decrease in plasma glucose under such circumstances. While these data do not establish that the drop in blood glucose is highly significant (P < 0.1 at 6 h) or is necessarily associated with the enhanced lethality per se, they would nevertheless support the concept that 50 mg of HS per kg injected after LPS has at least the potential to decrease plasma glucose and that the decreases may have contributed to the increased lethality.
DISCUSSION
We have demonstrated that pretreatment of mice with HS protects the animals against LPS lethality and that this protection depends on both HS dose and time of administration relative to LPS. Increasing the HS dose beyond a certain level or injecting the HS after the LPS not only eliminates its protective effects but increases the number of deaths.
The degree of protection afforded by HS may be assessed either by changes in the LD5,0 or from comparisons of relative lethality at given doses of LPS. Significant levels of Times of fasting, refeeding, HS injection, and LPS injection were the same as described in the legend to 3occll---,i,,,z,,X,z,,,,,,,0X,,z,z,,,z,,,z, "Times of fasting, refeeding, and LPS injection were the same as described in the legend to Fig. 1 . A dose of 50 mg of HS per kg was injected at 1450 h, 1.5 h after LPS. Data (three mice per datum point) are presented plus or minus the standard error of the mean.
b Following LPS injection. ' Controls were injected twice with the saline vehicle, first in place of LPS and then 1. protection against LPS lethality have been demonstrated previously by Berry and Smythe (4) using a protocol of simultaneous corticosteroid-LPS challenge. More recently, the work of Beutler et al. (8) has been extensively cited as demonstrating a role for TNF in LPS pathogenesis. In these studies significant protection was afforded mice treated with anti-TNF antibodies 2 h prior to LPS challenge. Finally, clinical trials using a human antiserum preparation with specificity for Escherichia coli J-5 have been reported by Ziegler et al. (42) to provide significant protection to patients with gram-negative sepsis, particularly those with negative blood cultures or those in profound shock. A comparison of the degree of protection afforded by each of these protecting agents against LPS with that obtained in the present study is presented in Table 3 , at doses corresponding in controls to LD50 and LD90. The protection afforded by HS pretreatment is clearly comparable to those obtained in the earlier studies of therapeutic interventions. Earlier observations that HS can bring about an increase in isolated hepatic PEPCK activity (32, 35) was extended in the present study to HS pretreatment of endotoxic mice. Under conditions that led to protection, the effect was of sufficient magnitude to eliminate the drop in PEPCK otherwise evident following the LPS. This was not, however, followed by an improvement in the level of plasma glucose. Also consistent with previous research is the observation (42) . For the LD50 determination, patients with negative blood culture were given human anti-J-5 antiserum at the time of diagnosis. For the LD,0 determination, patients were in profound shock. dThis study, Fig. 2A . Mouse lethality assay, 50 mg of HS per kg given 5 h prior to LPS challenge.
that HS in a sufficient dose can initially bring about a rapid drop in plasma glucose followed by a rapid return to control levels (32) . This was evident within the time period preceding the challenge.
The magnitude of the overall increases in PEPCK activity are also consistent with those found in previous research. What is perhaps noteworthy, however, is the time frame in which the elevated PEPCK levels are maintained. In this respect, PEPCK levels were still significantly elevated 17 h following the single HS injection, 12 h after LPS. Given that the half-life for hepatic PEPCK is only a few hours (17) , these results suggest that the liver is not only being continuously challenged to increase glucose production but that HS acts in response to that need over a considerable period of time. Given that PEPCK is subject to regulation by several hormones (11, 18, 38) , the hormonal basis for these changes is likely to prove complex and is currently under investigation, as is the finding that hepatic PEPCK was no longer sensitive to either HS pretreatment or LPS 24 h after LPS challenge.
The question then arises as to why corresponding improvement in the level of plasma glucose was not observed, and several possibilities might be proposed. First, the HSsustained increase in PEPCK might be offset by a continuing HS-induced inhibition of gluconeogenesis. Alternatively, HS may stimulate glucose clearance from the circulation. Either of these possibilities suggest that the HS-independent plasma glucose level may mask other glucose-related changes taking place. Still another possibility is that the HS-induced elevation of PEPCK simply does not have a major impact on gluconeogenesis in the LPS-challenged mice. In this regard, while it is clear that PEPCK activity can be rate limiting to gluconeogenesis, it need not be so under all circumstances (22) .
In any event, the question remains as to how HS might protect against LPS lethality, given that the overall level of plasma glucose was not improved. One possibility is that HS exerts its protective effect at an even more fundamental biochemical level with respect to endotoxic shock, possibly at the level of the macrophage, and against cachectin. In that regard, recent work from Cerami's laboratory demonstrated that the LPS-stimulated release of cachectin is critical to LPS lethality (39) . There is also increasing evidence that cytokines may be mediating many of the metabolically related effects of endotoxin (1, 14, 15, 19, 31) . The positive effect of HS on hepatic PEPCK in the LPS-challenged mice may be relevant here. In the event that this response reflects, at least in part, adrenal involvement, as was earlier suggested in studies with the normal rat (32) , then glucocorticoid-mediated protection emerges as an attractive possibility. Glucocorticoids are well established as protecting against LPS lethality (4). Moreover, dexamethasone has been shown to inhibit cachectin gene expression in macrophage culture (7) . As with HS protection against LPS lethality, the glucocorticoid must be delivered early in order to protect. Injection of glucocorticoid 1 or 2 h after the LPS dramatically reduces the degree of protection. In related studies, we have found that eliminating the capability of producing glucocorticoid by hypophysectomizing the mice not only makes the mice about 200-fold more sensitive to LPS but changes the effect of pretreatment with 50 mg of HS per kg from one of protecting against lethality to exacerbating lethality ( In that regard, tryptophan (16) and 3-mercaptopicolinate (20) each act similarly to HS in that they are hypoglycemiainhibiting in vivo at the point of PEPCK action, but each also gives rise to an increased hepatic PEPCK activity upon isolation. Moreover, Moon and Berry (29) found that injecting tryptophan at the same time as LPS has no effect on lethality but that tryptophan has an exacerbating effect when injected 4 h after the LPS. Perhaps the increased lethality seen in this instance, as with that seen from HS injected after the LPS or from HS pretreatment of hypophysectomized mice, may result from a diminished ability of the animal to respond to the initial stress. In regard to a decreased response capacity after LPS injection, it is well recognized that endotoxin brings about a complex resistance to hormonal stimulation of hepatic PEPCK synthesis (26, 30, 37) .
The results presented here clearly document an HSmediated protection of mice against the lethal effects of LPS. The effect, nevertheless, is critically dependent on the time of administration relative to LPS. Since all of the contributing factors to endotoxin-mediated pathophysiological changes leading to multiorgan failure and lethality have yet to be defined, an establishment of the biochemical mechanisms of HS-induced protection will be of value in elucidating the targets of endotoxic LPS in vivo. Our current experiments are aimed at defining the biochemical factors relevant to the observed HS protective effects.
